ArticleJournal of asthma and allergy2026
A Comparative Study of Type 2 Inflammatory Biomarkers Combined with Small Airway Parameters for Diagnosing Cough-Variant Asthma.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The diagnosis of cough-variant asthma (CVA) traditionally relies on clinical manifestations and bronchial provocation test (BPT). However, the BPT can be costly and complex, and poses risks of severe bronchospasm. Most CVA patients exhibit type 2 airway inflammation and small airway dysfunction. Identifying practical biomarkers such as total immunoglobulin E (tIgE), percentage of eosinophil cell count in induced sputum (sEOS%), peripheral blood eosinophil count (PBEC), and fractional exhaled nitric oxide (FeNO) may enhance the diagnostic process for cough-variant asthma. Objective: This study aims to evaluate and compare the diagnostic utility of T2 inflammatory biomarkers combined with small airway parameters for diagnosing CVA. Methods: This was a single-center, cross-sectional diagnostic study including 211 patients with chronic cough. Participants underwent spirometry, FeNO measurement, and assessment of eosinophilic inflammation, including sEOS%, PBEC, and tIgE. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance of individual parameters and combined models. Results: CVA was diagnosed in 27.5% of patients. Compared with non-CVA patients, those with CVA showed significantly higher levels of T2 inflammatory biomarkers and reduced small airway function. Among individual biomarkers, FeNO demonstrated the highest diagnostic accuracy (AUC = 0.79), followed by sEOS% (AUC = 0.75), tIgE (AUC = 0.71), and PBEC (AUC = 0.66). Among small airway parameters, FEF Conclusion: The combination of T2 inflammatory biomarkers and small airway function parameters improves the diagnostic accuracy for CVA. This approach may provide a practical and non-invasive strategy for identifying CVA, particularly in settings where bronchial provocation testing is not readily available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.